Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018571 · ClinicalTrials.gov registry record
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
A clinical trial of Dry Eye Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 946
- Enrollment target
- 1
- Study location
NCT06018571 is a study of Dry Eye Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 946 participants, above the 226-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (319% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06018571, a study of Dry Eye Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 946 participants
- Enrollment target
- 1
- Study location
Study Summary
This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is administered by Adelphi to a convenience sample of patients diagnosed with DED, and their consulting physicians in the United States. In addition to the survey data, the DED DSP also included recorded medical history data as reported by physicians (optometrists, ophthalmologists or refractive surgeons).
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 946 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2022-08-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06018571
The ClinicalTrials.gov registry entry for NCT06018571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 946 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 226-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (319% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06018571 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06018571 about?
NCT06018571 is a clinical study titled "Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US". This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is administered by Adelphi to a convenience sample of patients diagnosed with DED, and their consultin...
What is the current status of trial NCT06018571?
This trial is currently completed. The enrollment target is 946 participants. The study started on 2022-06-02. Estimated completion is 2022-08-19.
What conditions does trial NCT06018571 study?
This clinical trial studies the following conditions: Dry Eye Disease.
Who is sponsoring clinical trial NCT06018571?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018571 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
RECRUITING
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.